DOCSLIB.ORG

Michael Neuberger Obituary | Science | Theguardian.Com

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Michael Neuberger Obituary | Science | Theguardian.Com Michael Neuberger obituary | Science | theguardian.com http://www.theguardian.com/science/2013/dec/01/michael-ne... Search Michael Neuberger obituary Biochemist who discovered how antibodies are greatly improved KJ Patel theguardian.com, Sunday 1 December 2013 13.03 GMT Michael Neuberger developed mice that carried humanised antibody genes, with the aim of tricking the animal to produce humanised antibodies when confronted with specific targets. Photograph: MRC Laboratory of Molecular Biology The molecular biologist Michael Neuberger's research into antibodies did much to increase our understanding of how the body defends itself against microbes – single-cell organisms including viruses and bacteria. His own death at the age of 59 came, by sad coincidence, from myeloma, a cancer of the immune system leading to uncontrolled antibody production. When Neuberger was a PhD student at Imperial College London, his supervisor, Brian Hartley, suggested Neuberger visit the South African biologist Sydney Brenner at the MRC Laboratory of Molecular Biology (LMB) in Cambridge to collect some bacterial strains. Brenner spent several hours talking to Neuberger and the scale and scope of the discussion left his head spinning. As a consequence, Neuberger was drawn back to the LMB in 1980 and remained there for the rest of his career, eventually becoming its deputy director. 1 of 4 06/12/2013 12:46 Michael Neuberger obituary | Science | theguardian.com http://www.theguardian.com/science/2013/dec/01/michael-ne... But before that, Neuberger gained his PhD and on Brenner's advice spent two years in Cologne with Klaus Rajewsky. At the time Rajewsky was pioneering molecular techniques to understand the immune system. This experience led Neuberger to become interested in the biology of antibodies, proteins that are produced by B lymphocytes, a type of white blood cell, and are crucial in protecting us against microbes. Antibodies are remarkable molecules because they are tailor-made such that each individual antibody is directed to only one determinant – often a molecule specific to a microbe. This diversity is mainly achieved through a process of cutting and pasting back together a vast number of small gene fragments in the developing B lymphocyte. In Cambridge, the Nobel laureates César Milstein and Georges Köhler had achieved the isolation of an antibody of a single specificity and which can be produced in limitless quantities outside the body (mono-clonal antibodies). Neuberger began his research there against the background of these advances. He contributed significantly to knowledge of how B lymphocytes make antibodies, and these discoveries enabled him to genetically engineer antibody genes to produce novel types of antibodies. This work stimulated the subsequent development of therapeutic humanised antibodies by Neuberger's friend Sir Greg Winter. Neuberger's own specific contribution in this area lay in developing mice that carried humanised antibody genes, with the aim of tricking the animal to produce humanised antibodies when confronted with specific targets. Humanised antibodies are now transforming medicine and have engendered a multibillion pound industry. These advances ensured Neuberger's international reputation and his election as a fellow of the Royal Society in 1993. However, the most important of his numerous contributions to antibody research lay in the discovery of the mechanism by which the body greatly improves antibodies when the immune response to microbes is in full flight. In approaching this central problem, Neuberger knew that a process distinct from that of cutting and pasting of the antibody genes came into play when an antibody is in full demand. Something caused a tiny segment of the antibody gene to be showered with a vast number of alterations – or mutations. These mutations occurred at levels several million times higher than they do spontaneously throughout the rest of the genome in a cell. This process, known as somatic hypermutation, is crucial because the immune system can then exploit natural selection to enhance the efficacy of an antibody. At LMB, Milstein was already working on this, so they decided to collaborate. However, their approach was frustratingly slow. This prompted Neuberger to search for a much 2 of 4 06/12/2013 12:46 Michael Neuberger obituary | Science | theguardian.com http://www.theguardian.com/science/2013/dec/01/michael-ne... faster somatic hypermutating experimental system, and with a PhD student, Julian Sale, he made a breakthrough by discovering that certain B lymphocyte cell lines do indeed possess this property. The next step was to identify the hypermutator gene, but the race for this was cut short in 2000 by the identification by Tasuku Honjo of Kyoto University, Japan, of a gene called activation induced deaminase – or AID. Genetic inactivation of AID in man or mouse abolished hypermutation. The key question now shifted to defining precisely how the AID gene product mutated DNA. It seemed most likely that there was an indirect mechanism by which AID caused hypermutation, but these elaborate ideas led to considerable confusion. Neuberger then had the stunning insight that AID attacked DNA directly, stimulating the change of just one of the four bases in DNA. This tiny and subtle alteration, known as deamination, would then fool the normal DNA error-correcting mechanism to paradoxically introduce a mutation. Neuberger's lab confirmed his model and reported it in a letter to Nature in 2002. Up to his death, Neuberger co-headed a lab with Cristina Rada. Together they continued to study AID and its related molecules, specifically to understand how they were controlled so that they do not engage with DNA inappropriately. Indeed, it is now clear that when this happens, mutations rip through the genomes of cells, possibly explaining how they might subsequently become cancerous. Neuberger's deamination mechanism therefore has implications well beyond the alteration of antibody genes and for this reason he was awarded numerous international prizes. Michael was born in London, the son of Lillian and Albert Neuberger. His father was also an outstanding biochemist, and the PhD supervisor of the double Nobel prizewinner Frederick Sanger. For some years both father and son were fellows of the Royal Society. From Westminster school, Michael went on to read natural sciences at Trinity College, Cambridge, which he returned to as a research fellow in 1977 and later as director of studies. Despite his enormous scientific achievements, Neuberger was a very modest man with unique leadership skills. Those of us fortunate enough to have worked with him recollect visiting his tiny spartan office carrying our seemingly confusing data. One would then emerge with a sense of pure clarity, and of course a mountain of new experiments to do in order to pin down a discovery with absolute rigour. His students now run research teams at leading universities around the world. From 2002 onwards, Neuberger jointly headed the protein and nucleic acid chemistry division of the LMB, where previously Sanger, Milstein and another Nobel laureate, John Walker, had conducted their research. He ensured the continuation of its scientific 3 of 4 06/12/2013 12:46 Michael Neuberger obituary | Science | theguardian.com http://www.theguardian.com/science/2013/dec/01/michael-ne... vigour and world-class reputation. All this was achieved quietly, with no fuss, by force of personality and through a profound sense of duty. Neuberger was also sustained by a wonderful family life with his wife Gill Pyman, an Australian doctor, whom he married in 1991. She survives him, along with their two daughters and two sons. • Michael Neuberger, biochemist, born 2 November 1953; died 26 October 2013 More from the Guardian What's this? More from around the What's this? Paul Walker obituary 01 Dec 2013 web Having a child is nothing like deciding to buy a Porsche Airships – time for another lift-off? (EDF Pulse) 01 Dec 2013 10 Books that Will Change the Way You Think How football (aka soccer) made me wiser 01 Dec 2013 (Francesca Levy on LinkedIn) Male and female brains wired differently, scans reveal A really simple idea using an old jumper (Tesco 02 Dec 2013 Magazine) No need to be so gloomy about graphene 04 Dec 2013 If You Have Gmail, You Need This Trick (WebbROI) Living on a low income – tips (Money Advice Service) © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. 4 of 4 06/12/2013 12:46.
Load more

Recommended publications
  • Professor Michael Neuberger: Biochemist Behind Life-Saving
    Professor Michael Neuberger: Biochemist behind life-saving ... http://www.independent.co.uk/news/obituaries/professor-mich... THE INDEPENDENT FRIDAY 08 NOVEMBER 2013 NEWS VOICES SPORT TECH LIFE PROPERTY ARTS + ENTS TRAVEL MONEY INDYBEST BLOGS UK World Business People Science Environment Media Technology Education Obituaries Diary 1 of 15 08/11/2013 10:36 Professor Michael Neuberger: Biochemist behind life-saving ... http://www.independent.co.uk/news/obituaries/professor-mich... News > Obituaries Professor Michael Neuberger: Biochemist behind life-saving work on the immune system He was seen as an outstanding mentor, with his sharp intellect and ability to get to the core issue Friday 01 November 2013 Shares: 28 PRINT A A A FOOD+DRINK Professor Michael Neuberger was pivotal to the ADS BY GOOGLE great advances in biomedical research, with his You Could Be Owed unravelling of the mysteries of human £2400 If You've Ever Had A Loan antibodies. A Fellow of Trinity College, You Could Be Owed A Cambridge where he was a director of studies in Refund Natural Sciences, he was also deputy director of LloydsTSB.BankRefunds.ne t Cambridge’s Medical Research Council FreeWatt Solar PV Laboratory of Molecular Biology (LMB). Biomass Lincs Renewable Energy With the demand for a new class of drugs to Matcha the day: Company of 2012. Heard about the fight diseases, such as cancer, as well as immune Commercial & Domestic soft drink set to be Systems disorders such as rheumatoid arthritis, the the next big thing? www.freewatt.co.uk bio-tech industries have shown rapid growth. Buddhist monks Top10 Broadband in the Over 25 years, Neuberger made significant certainly have – they've UK been enjoying this Broadband From £2.50.
    [Show full text]
  • Fellowship, to the Crown
    2013 TRINITY COLLEGE cambridge trinity college cambridge annual record annual record 2013 Trinity College Cambridge Annual Record 2012–2013 Trinity College Cambridge CB2 1TQ Telephone: 01223 338400 e-mail: [email protected] website: www.trin.cam.ac.uk Cover photo: Aldous Bertram Contents 5 Editorial 9 The Master’s Installation Dinner 10 Speech of Welcome by Professor David McKitterick 13 Reply by Sir Gregory Winter 17 Commemoration 18 Chapel Address 22 The Health of the College 24 The Master’s Response on behalf of the College 29 Alumni Relations and Development 30 The Office and the Annual Fund 32 Alumni Associations 42 Annual Gatherings C 43 Alumni Achievements ontent 47 Benefactions 65 College Activities S 67 First & Third Trinity Boat Club 71 Field Club 88 Students’ Union and Societies 107 College Choir 109 Features 110 Heading South: Michael Proctor 112 Magnificent Seven: Trinity Men and Mrs Thatcher 118 Building the Bouncing Bomb: the Dambusters Raid seventy years on TRINITY ANNUAL RECORD 2013 3 131 Fellows, Staff and Students 132 The Master and Fellows 144 Appointments and Distinctions 149 In Memoriam 158 College Notes 167 The Register 168 In Memoriam 172 Addresses Wanted 191 An Invitation to Donate S content TRINITY ANNUAL RECORD 2013 | 4 Editorial The first highlight of the year occurred as early as 2 October when Sir Gregory Winter was installed as Master, just in time for a photograph of the ceremony to appear in our last edition. There were no speeches on that occasion, but on 30 November a special dinner was held, in lieu of the Audit Feast, to celebrate the Master’s installation.
    [Show full text]
  • Outputs, Outcomes and Impact of MRC Research: 2012 Report 10: Impacts on the Private Sector 10: Impacts on the Private Sector
    Outputs, outcomes and impact of MRC research: 2012 report 10: Impacts on the private sector 10: Impacts on the private sector Impacts on the private sector Summary The MRC is interested in the contribution that its research has made to the formation and growth of spin out companies. It is hoped that MRC research will lead to discoveries that can be commercially exploited and result in positive economic impacts such as employment, provision of new goods and services, and direct investment into the UK. The formation of spin out companies is one route to this. It is important that the MRC can both describe its contribution in this area and understand better the processes leading to the successful formation of spin out companies. The MRC is not suggesting that the setting up of spin out companies per se is a measure of success. We are interested in the downstream impact realised, as a result of pursuing this route to commercialisation. The MRC has had a spectacular track record in this area. Cambridge Antibody Technology (CAT), formed in 1989, is still noted as the only academic spin out which has resulted in the discovery of a blockbuster treatment (Humira). CAT was acquired by AstraZeneca in 2006 for £702 million, at which time CAT employed more than 300 staff. An earlier route to commercialising MRC research was the formation of Celltech by the National Enterprise Board in 1980, which floated on the stock exchange in 1993 and was bought by the Belgian Pharmaceutical company UCB in 2004 for £1.53 billion. At that time, Celltech employed around 1,900 people, 450 of which worked in research and development.
    [Show full text]
  • A Tribute to Michael S. Neuberger
    A tribute to Michael S. Neuberger Patricia J. Gearhart, Garnett Kelsoe J Clin Invest. 2014;124(1):3-5. https://doi.org/10.1172/JCI74366. Obituary Michael S. Neuberger, whose contributions to the field of molecular biology of B lymphocytes paved the way for humanizing therapeutic antibodies and understanding the genetic mechanisms of antibody expression, affinity maturation, and class switching, died October 26th, 2013, of multiple myeloma, at the age of 59 (Figure 1). Michael Neuberger was the youngest of four sons of the distinguished biochemist, Albert Neuberger, and his artist wife, Lilian. Albert Neuberger left Germany in 1933, as the Nazis came to power, and settled in London where he became a professor of chemical pathology. Remarkably, Fred Sanger, Albert Neuberger’s distinguished student, was the mentor of Cesar Milstein, who in turn, started Michael Neuberger along his own career. Neuberger studied biochemistry at the University of Cambridge and began his scientific career with Brian Hartley at Imperial College London, working on the evolution of enzymes in bacteria. His doctoral work earned him a research fellowship from Trinity College, Cambridge, where he sought out Milstein’s help to enter the new field of molecular immunology. Milstein offered him a position in the Medical Research Council Laboratory of Molecular Biology (LMB) but sent him first to the laboratory of Klaus Rajewsky in Cologne to “learn immunology.” After working in Germany for two years on immunoglobulin class-switched antibody pairs, Neuberger returned to the LMB where he began to study […] Find the latest version: https://jci.me/74366/pdf Obituary A tribute to Michael S.
    [Show full text]